| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/07/2010 | EP2170925A2 17ß -CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE |
| 04/07/2010 | EP2170920A1 Stable salts of s-adenosylmethionine and process for the preparation thereof |
| 04/07/2010 | EP2170907A2 Macrocycles and their uses |
| 04/07/2010 | EP2170905A2 Sirtuin modulating thiazolopyridine compounds |
| 04/07/2010 | EP2170903A1 Spiro ýpiperidine-4, 4' -thieno ý3, 2-c¨pyran¨derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| 04/07/2010 | EP2170901A1 Modulators of cystic fibrosis transmembrane conductance regulator |
| 04/07/2010 | EP2170899A1 Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function |
| 04/07/2010 | EP2170896A2 Polycyclic guanine derivatives and use thereof |
| 04/07/2010 | EP2170895A1 Sildenafil n-oxide as prodrug |
| 04/07/2010 | EP2170894A1 Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline |
| 04/07/2010 | EP2170893A1 Heterocyclic compounds and use thereof as erk inhibitors |
| 04/07/2010 | EP2170892A2 Imidazopyrazines as protein kinase inhibitors |
| 04/07/2010 | EP2170891A1 Pyrazolopyrimidinone kinase inhibitor |
| 04/07/2010 | EP2170888A1 Purine derivatives and their use as modulators of toll-like receptor 7 |
| 04/07/2010 | EP2170887A2 Heterocyclic compounds as raf kinase modulators |
| 04/07/2010 | EP2170886A1 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors |
| 04/07/2010 | EP2170885A1 Beta-carboline arylsulfonamides, method for preparing them and composition comprising them |
| 04/07/2010 | EP2170884A2 Chemical compounds |
| 04/07/2010 | EP2170883A1 Substituted fused pyrimidines as antagonists of gpr105 activity |
| 04/07/2010 | EP2170882A1 Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
| 04/07/2010 | EP2170881A1 Crystalline pyridazine compound |
| 04/07/2010 | EP2170879A1 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors |
| 04/07/2010 | EP2170878A1 Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition for preventing or treating osteoporosis comprising the same |
| 04/07/2010 | EP2170877A1 Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation |
| 04/07/2010 | EP2170876A2 Pharmaceutical composition for preventintion and treatment of restenosis comprising isoxazole derivatives |
| 04/07/2010 | EP2170875A1 Aminoalkylazole derivatives as histamine-3 antagonists |
| 04/07/2010 | EP2170874A2 Novel compounds and their use |
| 04/07/2010 | EP2170870A1 Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer |
| 04/07/2010 | EP2170866A1 Phthalazine compounds, compositions and methods of use |
| 04/07/2010 | EP2170864A1 Pyridone gpr119 g protein-coupled receptor agonists |
| 04/07/2010 | EP2170861A2 Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
| 04/07/2010 | EP2170859A1 Benzimidazole amido derivatives as kinase inhibitors |
| 04/07/2010 | EP2170857A2 3',4',5-trimethoxy flavone derivatives as stimulant of mucus secretion, method of the same, and pharmaceutical composition comprising the same |
| 04/07/2010 | EP2170852A1 1, 3 - dihydroxy substituted phenylamide glucokinase activators |
| 04/07/2010 | EP2170851A1 Modulators of pharmacokinetic properties of therapeutics |
| 04/07/2010 | EP2170850A1 Novel dicarboxylic acid derivatives as s1p1 receptor agonists |
| 04/07/2010 | EP2170848A1 Pyrazinone derivatives and their use in the treatment of lung diseases |
| 04/07/2010 | EP2170847A2 Substituted piperazines as cb1 antagonists |
| 04/07/2010 | EP2170846A2 Substituted piperazines as cb1 antagonists |
| 04/07/2010 | EP2170844A1 Novel polymorphs of erlotinib hydrochloride and method of preparation |
| 04/07/2010 | EP2170842A1 Protein kinase inhibitors and methods for using thereof |
| 04/07/2010 | EP2170841A1 Process for introduction of hydroxyethoxy side chain in bosentan |
| 04/07/2010 | EP2170839A1 Alkynylpyrimidines as tie2 kinase inhibitors |
| 04/07/2010 | EP2170838A1 Particulates of a crth2 antagonist |
| 04/07/2010 | EP2170836A1 Urea and carbamate derivatives as non-nucleoside reverse transcriptase inhibitors |
| 04/07/2010 | EP2170835A1 Process for preparing telmisartan |
| 04/07/2010 | EP2170834A1 Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases |
| 04/07/2010 | EP2170831A1 Benzazepine derivatives useful as vasopressin antagonists |
| 04/07/2010 | EP2170828A1 Substituted n-aryl pyridinones as fibrotic inhibitors |
| 04/07/2010 | EP2170827A2 Indolin-2-ones and aza-indolin-2-ones |
| 04/07/2010 | EP2170826A1 Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses |
| 04/07/2010 | EP2170824A1 Novel process |
| 04/07/2010 | EP2170819A1 Prostaglandin pharmaceutical compositions |
| 04/07/2010 | EP2170816A1 N-oxides of venlafaxine and o-desmethylvenlafaxine as prodrugs |
| 04/07/2010 | EP2170815A2 Renin inhibitors |
| 04/07/2010 | EP2170809A2 Methods for the preparation and formulation of l-carnitine valproate salts |
| 04/07/2010 | EP2170807A1 Spiro compounds useful as antagonists of the h1 receptor |
| 04/07/2010 | EP2170796A1 3-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-1-propanone and use thereof as an antimicrobial active ingredient |
| 04/07/2010 | EP2170404A2 Compositions comprising human egfr-sirna and methods of use |
| 04/07/2010 | EP2170403A2 Compositions and methods for inhibiting expression of pro-apoptotic genes |
| 04/07/2010 | EP2170399A1 Intranasal administration of asenapine and pharmaceutical compositions therefor |
| 04/07/2010 | EP2170398A1 Use of a synergistic composition as a therapeutic agent or disinfectant |
| 04/07/2010 | EP2170393A2 Antithrombotic agents and methods of use thereof |
| 04/07/2010 | EP2170354A1 Method for blocking ligation of the receptor for advanced glycation end-products (rage) |
| 04/07/2010 | EP2170352A1 Treatment of urinary tract infections with a mixture of saponin and an antibiotic |
| 04/07/2010 | EP2170351A2 Methods and compositions for treatment of cancer and other angiogenesis - related diseases |
| 04/07/2010 | EP2170350A2 Substituted imidazoheterocycles |
| 04/07/2010 | EP2170348A2 Effervescent tablets for inhalatory use |
| 04/07/2010 | EP2170347A1 Single-phase pharmaceutical composite preparation (dienogest and ethinyl estradiol) for oral therapy for regulation of blood pressure |
| 04/07/2010 | EP2170346A1 Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation |
| 04/07/2010 | EP2170345A1 Therapeutic substituted cyclopentanes for reducing intraocular pressure |
| 04/07/2010 | EP2170343A1 Treatment of age-related macular degeneration |
| 04/07/2010 | EP2170342A1 Compositions and methods for modulating inflammation using fluoroquinolones |
| 04/07/2010 | EP2170341A1 Salts of potassium atp channel openers and uses thereof |
| 04/07/2010 | EP2170340A2 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones |
| 04/07/2010 | EP2170336A1 Method for optimizing the treatment of chronic myeloid leukemia with abl tyrosine kinase inhibitors |
| 04/07/2010 | EP2170335A1 Compositions comprising tryptophan hydroxylase inhibitors |
| 04/07/2010 | EP2170334A1 Nmda receptor antagonists for neuroprotection |
| 04/07/2010 | EP2170333A2 Ranolazine for elevated brain-type natriuretic peptide |
| 04/07/2010 | EP2170332A1 A medicament for treating glaucoma comprising as an active ingredient cyclodextrin-clathrate compound of cilostazol |
| 04/07/2010 | EP2170329A2 Crystalline polymorph of 7-ethyl-10-hydroxycamptothecin |
| 04/07/2010 | EP2170328A2 Crystalline polymorph of exemestane |
| 04/07/2010 | EP2170327A2 Use of dopamine stabilizers |
| 04/07/2010 | EP2170326A2 Compositions for the treatment of hyperphenylalaninemia |
| 04/07/2010 | EP2170324A1 Compositions and methods for treating and preventing migrainous headaches and associated symptoms |
| 04/07/2010 | EP2170323A2 Crystalline rotigotine base and preparation process therefor |
| 04/07/2010 | EP2170322A1 METHODS OF MODIFYING AMYLOID ß OLIGOMERS USING NON-PEPTIDIC COMPOUNDS |
| 04/07/2010 | EP2170320A1 Use of piperine and derivatives thereof for the therapy of neurological conditions |
| 04/07/2010 | EP2170319A2 Solubilized formulation of docetaxel without tween 80 |
| 04/07/2010 | EP2170316A1 Improving memory in subjects with mini-mental state examination of 24-26 |
| 04/07/2010 | EP2170314A1 Methods and compositions for treating phenylketonuria |
| 04/07/2010 | EP2170313A2 Aqueous formulations of acetaminophen for injection |
| 04/07/2010 | EP2170312A1 Method of preventing and treating acute brain pathologies |
| 04/07/2010 | EP2170311A1 Compounds and methods for treating or preventing autoimmune diseases |
| 04/07/2010 | EP2170310A2 Quick dissolve compositions of memantine hydrochloride |
| 04/07/2010 | EP2170309A1 Methods and compositions for treating disorders |
| 04/07/2010 | EP2170307A2 Inhibition of age formation |
| 04/07/2010 | EP2170306A1 Methods of treating serotonin-mediated diseases and disorders |
| 04/07/2010 | EP2170305A1 Transdermal delivery system comprising glycopyrrolate to treat sialorrhea |
| 04/07/2010 | EP2170300A2 Microspheres having core/shell structure |